SEC ownership of XOMA Royalty Corp

Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0000791908.

Comparable stake leader

LIGAND PHARMACEUTICALS INC

Disclosed value leader

BIOTECHNOLOGY VALUE FUND L P

Comparable rows

50/50

Latest evidence

21 May 2026

Top shareholders Insider holders Latest transactions
Public ticker
XOMA, XOMAO, XOMAP on Nasdaq
Parsed ownership sources
13D/G, 3/4/5, and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
Largest SEC-reported holder
LIGAND PHARMACEUTICALS INC
Ranking: Comparable ownership first, then disclosed value
Ownership snapshot CIK-linked ownership evidence from parsed SEC filings. 3 signals
Comparable ownership rows
50 of 50
Meaning: Rows with safely comparable ownership %
Latest 13D/G holder
LIGAND PHARMACEUTICALS INC
Source: Latest parsed Schedule 13D/G stake
Latest parsed ownership date
21 May 2026
Freshness: Most recent filing date in this holder set
Issuer Names, identifiers, and filing context for this profile. 2 identity fields
Issuer CIK
0000791908
Issuer location
Emeryville, CA

Ownership snapshot

Top shareholders of XOMA Royalty Corp (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
LIGAND PHARMACEUTICALS INC
Disclosed value leader
BIOTECHNOLOGY VALUE FUND L P
Comparable rows
50/50
Latest evidence
21 May 2026
13D/G 3/4/5 13F Lead comparable stake: 47% 13D/G row: LIGAND PHARMACEUTICALS INC Showing 1-8 of 50 holder rows.

Quick read

LIGAND PHARMACEUTICALS INC leads the comparable SEC ownership view at 47%.

50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens LIGAND PHARMACEUTICALS INC's linked filing trail.
Comparable ownership Top 5
LIGAND PHARMACEUTICALS INC 47%
BIOTECHNOLOGY VALUE FUND L P 43%
MORGAN STANLEY 14%
FMR LLC 10%
Woodline Partners LP 5.4%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-8 of 50 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
LIGAND PHARMACEUTICALS INC
13D/G
Ligand Pharmaceuticals Incorporated
13D/G
47%
$311,622,505
8,062,678 shares
 $0 27 Apr 2026
BIOTECHNOLOGY VALUE FUND L P
13D/G 3/4/5
BVF PARTNERS L P/IL · 10%+ Owner
13D/G 3/4/5
43%
$318,690,927
7,593,303 shares
 +$209,975,910 14 May 2026
MORGAN STANLEY
13F 13D/G
Company
13F 13D/G
14%
from 13D/G
$53,396,665
1,702,157 shares
 — 31 Mar 2026
FMR LLC
13F 13D/G
Company
13F 13D/G
10%
from 13D/G
$40,874,300
1,302,974 shares
 — 31 Mar 2026
Woodline Partners LP
13D/G 13F
Company
13D/G 13F
5.4%
$24,736,039
640,001 shares
 $0 31 Mar 2026
BlackRock, Inc.
13F 13D/G
Company
13F 13D/G
5.4%
from 13D/G
$20,293,692
646,914 shares
 — 31 Mar 2026
VANGUARD CAPITAL MANAGEMENT LLC
13D/G 13F
Vanguard Capital Management · Company
13D/G 13F
5.2%
$19,244,177
613,458 shares
 $0 31 Mar 2026
BVF INC/IL
13F 3/4/5
Company · 10%+ Owner
13F 3/4/5
6.8%
from 3/4/5
$81,257,805
2,590,303 shares
 — 31 Mar 2026
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Forms 3/4/5 flow

Insider trading overview

Net insider flow leans to buying over the last 12 months. Net value: +$2,349,180.

Buys
$2,505,000
Insiders: 1
Sells
$155,820
Insiders: 1
Net
+$2,349,180
Shares: +95,670
Window
Last 12 months
4 rolling buckets
Buy value Sell value
Shares: 100,000 Shares: 4,330
Window (months) Buy shares Sell shares Buy value Sell value Net value
0-3 0 0 $0 $0 $0
3-6 0 0 $0 $0 $0
6-9 100,000 0 $2,505,000 $0 +$2,505,000
9-12 0 4,330 $0 $155,820 -$155,820

Reporting owners

Insider holders from Forms 3/4/5

Showing 1-20 of 23 reporting-owner rows connected to XOMA Royalty Corp. Open a relationship link for the CIK-to-CIK filing trail.

Rows
23
Largest Forms 3/4/5 holder
BVF PARTNERS L P/IL
Net 12M change
+$2,349,180
Latest report
21 May 2026
Name Relationship Holdings Value Past Year Net Change Change % Valuation Report Date
BVF PARTNERS L P/IL 10%+ Owner $66,280,320 Mixed 14 May 2026
BIOTECHNOLOGY VALUE FUND L P 10%+ Owner $37,142,080 Median 14 May 2026
Mark N. Lampert 10%+ Owner $37,142,080 Median 14 May 2026
BVF INC/IL 10%+ Owner $37,142,080 Median 14 May 2026
BVF GP HOLDINGS LLC 10%+ Owner $37,142,080 Median 14 May 2026
BVF Partners OS Ltd. Other* $37,142,080 Median 14 May 2026
Biotechnology Value Trading Fund OS LP Other* $37,142,080 Median 14 May 2026
BVF I GP LLC 10%+ Owner $37,142,080 Median 14 May 2026
BVF II GP LLC 10%+ Owner $37,142,080 Median 14 May 2026
BIOTECHNOLOGY VALUE FUND II LP 10%+ Owner $37,142,080 Median 14 May 2026
Owen Hughes Chief Executive Officer, Director $11,642,731 +$2,505,000 +27% Mixed 20 Apr 2026
Thomas M. Burns SVP, Finance & CFO $3,626,717 -$155,820 -4.1% Mixed 19 Sep 2025
Jeffrey Trigilio Chief Financial Officer $3,259,448 Median 20 Apr 2026
Bradley Sitko Chief Investment Officer $3,063,986 Mixed 20 Apr 2026
Maricel Perea Montano Chief Legal Officer $1,311,012 Median 20 Apr 2026
Joseph M. Limber Director $1,163,163 Mixed 21 May 2026
Matthew D. Perry Director $860,353 Median 21 May 2026
Jack L. Wyszomierski Director $787,888 Median 21 May 2026
James R. Neal CEO, Director $636,556 Mixed 15 Jul 2022
Natasha Hernday Director $395,011 Median 21 May 2026

Recent insider transactions for XOMA Royalty Corp

Showing up to 300 recent insider transactions from the last 12 months.

Insider Symbol Class Transaction % SEC-reported value SEC-reported price Shares Shares owned Date Ownership
Jack L. Wyszomierski XOMA Common Stock Award 16.7% 3,586 25,116 21 May 2026 Direct
Joseph M. Limber XOMA Common Stock Award 38.8% 3,586 12,820 21 May 2026 Direct
Natasha Hernday XOMA Common Stock Award 39.8% 3,586 12,592 21 May 2026 Direct
Matthew D. Perry XOMA Common Stock Award 15% 3,586 27,426 21 May 2026 Direct
Heather L. Franklin XOMA Common Stock Award 60.1% 3,586 9,557 21 May 2026 Direct
Barbara Kosacz XOMA Common Stock Award 60.1% 3,586 9,557 21 May 2026 Direct
BVF PARTNERS L P/IL XOMA Common Stock, $0.0075 par value per share Conversion of derivative security 772,000 772,000 14 May 2026 See footnote
Bvf Partners L P/Il XOMA Common Stock, $0.0075 par value per share Conversion of derivative security 772,000 772,000 14 May 2026 See footnote
Bvf Partners L P/Il XOMA Common Stock, $0.0075 par value per share Conversion of derivative security 772,000 772,000 14 May 2026 See footnote
Bvf Partners L P/Il XOMA Common Stock, $0.0075 par value per share Conversion of derivative security 772,000 772,000 14 May 2026 See footnote
Bvf Partners L P/Il XOMA Common Stock, $0.0075 par value per share Conversion of derivative security 772,000 772,000 14 May 2026 See footnote
Bvf Partners L P/Il XOMA Common Stock, $0.0075 par value per share Conversion of derivative security 772,000 772,000 14 May 2026 See footnote
Bvf Partners L P/Il XOMA Common Stock, $0.0075 par value per share Conversion of derivative security 772,000 772,000 14 May 2026 See footnote
Bvf Partners L P/Il XOMA Common Stock, $0.0075 par value per share Conversion of derivative security 772,000 772,000 14 May 2026 See footnote
Bvf Partners L P/Il XOMA Common Stock, $0.0075 par value per share Conversion of derivative security 772,000 772,000 14 May 2026 See footnote
Bvf Partners L P/Il XOMA Common Stock, $0.0075 par value per share Conversion of derivative security 772,000 772,000 14 May 2026 See footnote
BVF PARTNERS L P/IL XOMA Common Stock, $0.0075 par value per share Conversion of derivative security 4,231,000 3,635,758 14 May 2026 Direct
Bvf Partners L P/Il XOMA Common Stock, $0.0075 par value per share Conversion of derivative security 4,231,000 3,635,758 14 May 2026 Direct
Bvf Partners L P/Il XOMA Common Stock, $0.0075 par value per share Conversion of derivative security 4,231,000 3,635,758 14 May 2026 Direct
Bvf Partners L P/Il XOMA Common Stock, $0.0075 par value per share Conversion of derivative security 4,231,000 3,635,758 14 May 2026 Direct
Bvf Partners L P/Il XOMA Common Stock, $0.0075 par value per share Conversion of derivative security 4,231,000 3,635,758 14 May 2026 Direct
Bvf Partners L P/Il XOMA Common Stock, $0.0075 par value per share Conversion of derivative security 4,231,000 3,635,758 14 May 2026 Direct
Bvf Partners L P/Il XOMA Common Stock, $0.0075 par value per share Conversion of derivative security 4,231,000 3,635,758 14 May 2026 Direct
Bvf Partners L P/Il XOMA Common Stock, $0.0075 par value per share Conversion of derivative security 4,231,000 3,635,758 14 May 2026 Direct
Bvf Partners L P/Il XOMA Common Stock, $0.0075 par value per share Conversion of derivative security 4,231,000 3,635,758 14 May 2026 Direct
Bvf Partners L P/Il XOMA Common Stock, $0.0075 par value per share Conversion of derivative security 4,231,000 3,635,758 14 May 2026 Direct
BVF PARTNERS L P/IL XOMA Series X Convertible Preferred Stock Conversion of derivative security -100% -772 0 14 May 2026 See footnote
Bvf Partners L P/Il XOMA Series X Convertible Preferred Stock Conversion of derivative security -100% -772 0 14 May 2026 See footnote
Bvf Partners L P/Il XOMA Series X Convertible Preferred Stock Conversion of derivative security -100% -772 0 14 May 2026 See footnote
Bvf Partners L P/Il XOMA Series X Convertible Preferred Stock Conversion of derivative security -100% -772 0 14 May 2026 See footnote
Bvf Partners L P/Il XOMA Series X Convertible Preferred Stock Conversion of derivative security -100% -772 0 14 May 2026 See footnote
Bvf Partners L P/Il XOMA Series X Convertible Preferred Stock Conversion of derivative security -100% -772 0 14 May 2026 See footnote
Bvf Partners L P/Il XOMA Series X Convertible Preferred Stock Conversion of derivative security -100% -772 0 14 May 2026 See footnote
Bvf Partners L P/Il XOMA Series X Convertible Preferred Stock Conversion of derivative security -100% -772 0 14 May 2026 See footnote
Bvf Partners L P/Il XOMA Series X Convertible Preferred Stock Conversion of derivative security -100% -772 0 14 May 2026 See footnote
Bvf Partners L P/Il XOMA Series X Convertible Preferred Stock Conversion of derivative security -100% -772 0 14 May 2026 See footnote
BVF PARTNERS L P/IL XOMA Series X Convertible Preferred Stock Conversion of derivative security -100% -4,231 0 14 May 2026 Direct
Bvf Partners L P/Il XOMA Series X Convertible Preferred Stock Conversion of derivative security -100% -4,231 0 14 May 2026 Direct
Bvf Partners L P/Il XOMA Series X Convertible Preferred Stock Conversion of derivative security -100% -4,231 0 14 May 2026 Direct
Bvf Partners L P/Il XOMA Series X Convertible Preferred Stock Conversion of derivative security -100% -4,231 0 14 May 2026 Direct
Bvf Partners L P/Il XOMA Series X Convertible Preferred Stock Conversion of derivative security -100% -4,231 0 14 May 2026 Direct
Bvf Partners L P/Il XOMA Series X Convertible Preferred Stock Conversion of derivative security -100% -4,231 0 14 May 2026 Direct
Bvf Partners L P/Il XOMA Series X Convertible Preferred Stock Conversion of derivative security -100% -4,231 0 14 May 2026 Direct
Bvf Partners L P/Il XOMA Series X Convertible Preferred Stock Conversion of derivative security -100% -4,231 0 14 May 2026 Direct
Bvf Partners L P/Il XOMA Series X Convertible Preferred Stock Conversion of derivative security -100% -4,231 0 14 May 2026 Direct
Bvf Partners L P/Il XOMA Series X Convertible Preferred Stock Conversion of derivative security -100% -4,231 0 14 May 2026 Direct
Jeffrey Trigilio XOMA Common Stock Options Exercise 12.5% 11,538 103,906 20 Apr 2026 Direct
Jeffrey Trigilio XOMA Performance Stock Units Options Exercise -8.33% -11,538 126,924 20 Apr 2026 Direct
Maricel Perea Montano XOMA Common Stock Options Exercise 8.77% 3,370 41,793 20 Apr 2026 Direct
Maricel Perea Montano XOMA Performance Stock Units Options Exercise -8.33% -3,370 37,074 20 Apr 2026 Direct
* marks a reported price that did not pass the local price check.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .